Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain

Jillian Whidby, Guaniri Mateu, Hannah Scarborough, Borries Demeler, Arash Grakoui, Joseph Marcotrigiano

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

More than 120 million people worldwide are chronically infected with hepatitis C virus (HCV), making HCV infection the leading cause of liver transplantation in developed countries. Treatment is limited, and efficacy depends upon the infecting strain and the initial viral load. The HCV envelope glycoproteins (E1 and E2) are involved in receptor binding, virus-cell fusion, and entry into the host cell. HCV infection proceeds by endosomal acidification, suggesting that fusion of the viral envelope with cellular membranes is a pH-triggered event. E2 consists of an amino-terminal ectodomain, an amphipathic helix that forms a stem region, and a carboxy-terminal membrane-associating segment. We have devised a novel expression system for the production of a secreted form of E2 ectodomain (eE2) from mammalian cells and performed a comprehensive biochemical and biophysical characterization. eE2 is properly folded, as determined by binding to human CD81, blocking of infection of cell culture-derived HCV, and recognition by antibodies from patients chronically infected with different genotypes of HCV. The glycosylation pattern, number of disulfide bonds, oligomerization state, and secondary structure of eE2 have been characterized using mass spectrometry, size exclusion chromatography, circular dichroism, and analytical ultracentrifugation. These results advance the understanding of E2 and may assist in the design of an HCV vaccine and entry inhibitor.

Original languageEnglish (US)
Pages (from-to)11078-11089
Number of pages12
JournalJournal of Virology
Volume83
Issue number21
DOIs
StatePublished - Nov 2009

Fingerprint

Hepatitis C virus
Virus Diseases
Hepacivirus
infection
Proteins
proteins
Virus Receptors
Virus Attachment
Virus Internalization
Hepatitis C Antibodies
Membranes
Cell Fusion
Ultracentrifugation
Circular Dichroism
Viral Load
Glycosylation
circular dichroism spectroscopy
Developed Countries
Disulfides
Liver Transplantation

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Whidby, J., Mateu, G., Scarborough, H., Demeler, B., Grakoui, A., & Marcotrigiano, J. (2009). Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain. Journal of Virology, 83(21), 11078-11089. https://doi.org/10.1128/JVI.00800-09

Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain. / Whidby, Jillian; Mateu, Guaniri; Scarborough, Hannah; Demeler, Borries; Grakoui, Arash; Marcotrigiano, Joseph.

In: Journal of Virology, Vol. 83, No. 21, 11.2009, p. 11078-11089.

Research output: Contribution to journalArticle

Whidby, J, Mateu, G, Scarborough, H, Demeler, B, Grakoui, A & Marcotrigiano, J 2009, 'Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain', Journal of Virology, vol. 83, no. 21, pp. 11078-11089. https://doi.org/10.1128/JVI.00800-09
Whidby J, Mateu G, Scarborough H, Demeler B, Grakoui A, Marcotrigiano J. Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain. Journal of Virology. 2009 Nov;83(21):11078-11089. https://doi.org/10.1128/JVI.00800-09
Whidby, Jillian ; Mateu, Guaniri ; Scarborough, Hannah ; Demeler, Borries ; Grakoui, Arash ; Marcotrigiano, Joseph. / Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain. In: Journal of Virology. 2009 ; Vol. 83, No. 21. pp. 11078-11089.
@article{39b4cf9e85c2422fb7e834c2a009e12f,
title = "Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain",
abstract = "More than 120 million people worldwide are chronically infected with hepatitis C virus (HCV), making HCV infection the leading cause of liver transplantation in developed countries. Treatment is limited, and efficacy depends upon the infecting strain and the initial viral load. The HCV envelope glycoproteins (E1 and E2) are involved in receptor binding, virus-cell fusion, and entry into the host cell. HCV infection proceeds by endosomal acidification, suggesting that fusion of the viral envelope with cellular membranes is a pH-triggered event. E2 consists of an amino-terminal ectodomain, an amphipathic helix that forms a stem region, and a carboxy-terminal membrane-associating segment. We have devised a novel expression system for the production of a secreted form of E2 ectodomain (eE2) from mammalian cells and performed a comprehensive biochemical and biophysical characterization. eE2 is properly folded, as determined by binding to human CD81, blocking of infection of cell culture-derived HCV, and recognition by antibodies from patients chronically infected with different genotypes of HCV. The glycosylation pattern, number of disulfide bonds, oligomerization state, and secondary structure of eE2 have been characterized using mass spectrometry, size exclusion chromatography, circular dichroism, and analytical ultracentrifugation. These results advance the understanding of E2 and may assist in the design of an HCV vaccine and entry inhibitor.",
author = "Jillian Whidby and Guaniri Mateu and Hannah Scarborough and Borries Demeler and Arash Grakoui and Joseph Marcotrigiano",
year = "2009",
month = "11",
doi = "10.1128/JVI.00800-09",
language = "English (US)",
volume = "83",
pages = "11078--11089",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "21",

}

TY - JOUR

T1 - Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain

AU - Whidby, Jillian

AU - Mateu, Guaniri

AU - Scarborough, Hannah

AU - Demeler, Borries

AU - Grakoui, Arash

AU - Marcotrigiano, Joseph

PY - 2009/11

Y1 - 2009/11

N2 - More than 120 million people worldwide are chronically infected with hepatitis C virus (HCV), making HCV infection the leading cause of liver transplantation in developed countries. Treatment is limited, and efficacy depends upon the infecting strain and the initial viral load. The HCV envelope glycoproteins (E1 and E2) are involved in receptor binding, virus-cell fusion, and entry into the host cell. HCV infection proceeds by endosomal acidification, suggesting that fusion of the viral envelope with cellular membranes is a pH-triggered event. E2 consists of an amino-terminal ectodomain, an amphipathic helix that forms a stem region, and a carboxy-terminal membrane-associating segment. We have devised a novel expression system for the production of a secreted form of E2 ectodomain (eE2) from mammalian cells and performed a comprehensive biochemical and biophysical characterization. eE2 is properly folded, as determined by binding to human CD81, blocking of infection of cell culture-derived HCV, and recognition by antibodies from patients chronically infected with different genotypes of HCV. The glycosylation pattern, number of disulfide bonds, oligomerization state, and secondary structure of eE2 have been characterized using mass spectrometry, size exclusion chromatography, circular dichroism, and analytical ultracentrifugation. These results advance the understanding of E2 and may assist in the design of an HCV vaccine and entry inhibitor.

AB - More than 120 million people worldwide are chronically infected with hepatitis C virus (HCV), making HCV infection the leading cause of liver transplantation in developed countries. Treatment is limited, and efficacy depends upon the infecting strain and the initial viral load. The HCV envelope glycoproteins (E1 and E2) are involved in receptor binding, virus-cell fusion, and entry into the host cell. HCV infection proceeds by endosomal acidification, suggesting that fusion of the viral envelope with cellular membranes is a pH-triggered event. E2 consists of an amino-terminal ectodomain, an amphipathic helix that forms a stem region, and a carboxy-terminal membrane-associating segment. We have devised a novel expression system for the production of a secreted form of E2 ectodomain (eE2) from mammalian cells and performed a comprehensive biochemical and biophysical characterization. eE2 is properly folded, as determined by binding to human CD81, blocking of infection of cell culture-derived HCV, and recognition by antibodies from patients chronically infected with different genotypes of HCV. The glycosylation pattern, number of disulfide bonds, oligomerization state, and secondary structure of eE2 have been characterized using mass spectrometry, size exclusion chromatography, circular dichroism, and analytical ultracentrifugation. These results advance the understanding of E2 and may assist in the design of an HCV vaccine and entry inhibitor.

UR - http://www.scopus.com/inward/record.url?scp=70350316185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350316185&partnerID=8YFLogxK

U2 - 10.1128/JVI.00800-09

DO - 10.1128/JVI.00800-09

M3 - Article

C2 - 19710151

AN - SCOPUS:70350316185

VL - 83

SP - 11078

EP - 11089

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 21

ER -